Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $19.27M (cash outflow) fell 28.3% year over year, behind the -21.5% change in trailing-twelve-month net income. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$62.42M (-31.1%) for the fiscal year ending Dec 2026, a slowdown from the -18.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.27M-4.5% QoQ
Last fiscal yearDec 2025
-$90.6M-18.5% YoY
LTMMar 2026
-$83.01M-21.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.3%-57.8%-29.5 pp
1 year-18.5%-31.1%-12.6 pp
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(90.6M) USD
Year-over-year change
+18.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's LTM Mar 2026 net income of $83.01M is the 4th largest of the 11 companies compared; the peer median is $76.56M.
  • Its year-over-year change of -21.5% is the 9th highest of 11, against a peer median of -10.9%.
  • Net income amounts to 36891.1% of revenue for TNYA, versus a peer median of 460.1%.
TNYA Competitors Peer median
Net Income for TNYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$133.22M -9.9%+14.2%1189.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M +25.7%+50.6%4840.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M -21.5%-9.9%36891.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$81.74M -14.2%-13.0%589.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$77.8M -39.1%-4.8%465.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$66.14M +249.7%—454.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M -35.7%-12.4%89.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$57.09M -16.9%+0.6%—
IMRXImmuneering CorporationLTM Mar 2026$54.44M -11.9%+3.5%—
Peer median (excluding TNYA) $76.56M-10.9%+0.6%460.1%

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Depreciation & Amortization2.96M6.47M8.69M8.47M8.85M
Deferred Income Tax00000
Stock-Based Compensation2.95M11.47M15.31M16.5M13.05M
Change in Working Capital4.74M(849K)(5.65M)(7.93M)(2.46M)
Accounts Receivables00000
Inventory00000
Accounts Payables8.6M1.66M(3.28M)(581K)(1.43M)
Other Working Capital(3.86M)(2.51M)(2.37M)(7.35M)(1.03M)
Other Non-Cash Items1.26M2.16M3.66M3.59M2.9M
Operating Cash Flow(60.81M)(104.42M)(102.07M)(90.5M)(68.26M)
Capital Expenditures(25.12M)(20.63M)(1.24M)(1.03M)(618K)
Acquisitions (Net)00000
Purchases of Investments(213.44M)(140.48M)(56.64M)(87.07M)0
Sales of Investments0244.75M106.62M89.21M56.7M
Other Investing Activities08K(25K)17K0
Investing Cash Flow(238.56M)83.65M48.72M1.13M56.08M
Debt Repayment00000
Common Stock Issued188.54M77.39M3.87M46.76M108.41M
Common Stock Repurchased(13K)0000
Dividends Paid00000
Other Financing Activities461K380K181K987K0
Financing Cash Flow208.97M77.77M4.05M47.75M108.41M
Effect of Forex Changes00000
Net Change in Cash(90.41M)57M(49.31M)(41.62M)96.22M
Free Cash Flow(85.93M)(125.05M)(103.31M)(91.53M)(68.88M)

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.